GH Research (NASDAQ:GHRS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of GH Research (NASDAQ:GHRS) from a sell rating to a hold rating in a research note published on Saturday morning.

GHRS has been the topic of several other research reports. Zacks Research lowered GH Research from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a research report on Friday, July 17th. Guggenheim lifted their price target on shares of GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday. Needham & Company LLC boosted their price target on shares of GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a report on Thursday. Finally, HC Wainwright dropped their price objective on shares of GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, GH Research has an average rating of “Moderate Buy” and an average price target of $42.78.

GH Research Stock Performance

NASDAQ GHRS opened at $30.27 on Friday. The firm has a 50-day simple moving average of $25.70 and a 200 day simple moving average of $20.16. GH Research has a twelve month low of $11.32 and a twelve month high of $31.44. The stock has a market cap of $2.08 billion, a PE ratio of -30.27 and a beta of 1.29.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.06. Research analysts forecast that GH Research will post -1.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GH Research

Several institutional investors and hedge funds have recently made changes to their positions in the company. Lynx1 Capital Management LP grew its holdings in shares of GH Research by 27.5% in the 3rd quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after purchasing an additional 1,854,238 shares during the last quarter. RTW Investments LP lifted its holdings in GH Research by 6.5% during the 4th quarter. RTW Investments LP now owns 5,933,815 shares of the company’s stock valued at $75,359,000 after purchasing an additional 364,251 shares during the last quarter. Avoro Capital Advisors LLC acquired a new position in GH Research in the fourth quarter valued at about $22,860,000. Troluce Capital Advisors LLC boosted its position in GH Research by 165.4% in the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after buying an additional 617,260 shares in the last quarter. Finally, Millennium Management LLC boosted its position in GH Research by 324.1% in the third quarter. Millennium Management LLC now owns 863,602 shares of the company’s stock valued at $12,350,000 after buying an additional 659,957 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.